866-997-4948(US-Canada Toll Free)

Nimotuzumab (Head and Neck Cancer) - Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Head and Neck Cancer

No. of Pages : 42 Pages


Summary

GlobalDatas pharmaceuticals report, Nimotuzumab (Head and Neck Cancer) - Analysis and Forecasts to 2020 provides Nimotuzumab sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Head and Neck cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Nimotuzumab including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Nimotuzumab including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2015-2020 for Nimotuzumab in each of the US, EU5 and Japan.

Reasons to buy

 

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

 

Table of Content

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Head and Neck Cancer Market 4
2.2 Epidemiology 4
2.3 Etiology 8
2.4 GlobalData Pipeline Report Guidance 9


3 Head and Neck Cancer Disease: Market Characterization 10
3.1 Head and Neck Cancer Disease Market 10
3.2 Head and Neck Cancer Disease Market Forecasts and CAGR 10
3.3 Drivers for the Head and Neck Cancer Disease Market 11
3.3.1 High Incidence 11
3.3.2 Low Initial Diagnosis Rate 12
3.3.3 Emergence of Targeted Therapies and Vaccines 12


4 TNM Classification of Head and Neck Cancer 13


5 Nimotuzumab 21
5.1 Introduction 21
5.2 Mechanism of Action 21
5.3 Clinical Studies 21
5.4 Approval History of Nimotuzumab 22
5.5 Sales drivers 22
5.5.1 Head and neck cancer Market 22
5.5.2 Targeted therapy 23
5.5.3 Better safety 23
5.5.4 Better Efficacy 24
5.6 Drug Evaluation 24
5.6.1 Drug Risk Benefit Score 24
5.6.2 Intensity of Competition 26
5.7 Sales forecast 26
5.7.1 Target patient Pool of Nimotuzumab 26
5.7.2 Market Penetration 27
5.7.3 Dosing 27
5.7.4 Annual Cost of Therapy 28
5.7.5 Sales Projections of Nimotuzumab 28


6 Head and Neck Cancer Market: Appendix 37
6.1 Market Definitions 37
6.2 Abbreviations 37
6.3 Research Methodology 38
6.3.1 Coverage 38
6.3.2 Secondary Research 39
6.3.3 Forecasting 39
6.3.4 Number of Patients Approved to take the Drug 39
6.3.5 Net Penetration of Drug 39
6.3.6 Net Annual Dosing 41
6.3.7 Annual Cost of Therapy 41
6.3.8 Primary Research 41
6.3.9 Expert Panels 41
6.4 Contact Us 41
6.5 Disclaimer 42
6.6 Sources 42

List of Table


Table 1: Head and Neck Cancer Incidences and Mortality, 2008-2030 4
Table 2: Head and Neck Cancer, Market Forecasts ($bn), Global, 20092020 10
Table 3: TNM Classification of the Oral cavity, Larynx, Oropharynx and Hypopharyngeal Cancers 13
Table 4: TNM Classification of the Nasopharyngeal Cancer 18
Table 5: Completed Clinical Studies 21
Table 6: Ongoing Clinical Studies 21
Table 7: Percentage of patients having EGFR expression for different types of cancer 23
Table 8: Drug Risk Benefit Score (DRB)-Nimotuzumab 24
Table 9: Clinical Study results summary 25
Table 10: Safety profile of Leading EGFR targeting drugs compared with Nimotuzumab 26
Table 11: Nimotuzumab , Head and Neck cancer, Global Sales Forecast ($m), 20152020 28
Table 12: Nimotuzumab , Head and Neck cancer, the US Sales Forecast ($m), 20152020 29
Table 13: Nimotuzumab , Head and Neck cancer, the UK Sales Forecast ($m), 20152020 30
Table 14: Nimotuzumab , Head and Neck cancer, France Sales Forecast ($m), 20152020 31
Table 15: Nimotuzumab , Head and Neck cancer, Germany Sales Forecast ($m), 20152020 32
Table 16: Nimotuzumab , Head and Neck cancer, Italy Sales Forecast ($m), 20152020 33
Table 17: Nimotuzumab , Head and Neck cancer, Spain Sales Forecast ($m), 20152020 34
Table 18: Nimotuzumab , Head and Neck cancer, Japan Sales Forecast ($m), 20152020 35

List of Chart


Figure 1: Percentage Distribution of Top 20 Cancers, Based on Incidence Global, 2008 5
Figure 2: Percentage Distribution of Top 20 Cancers, Based on Mortality Global, 2008 6
Figure 3: Difference Between Distribution of Incidence and Mortality of Top 20 Cancers , 2008 6
Figure 4: Distribution of Cancer Types in Head and Neck US, EU-5 and Japan ,2008 7
Figure 5: Distribution of Cancer Types in Head and Neck ,Global, 2008 7
Figure 6: Per Capita Cigarette Consumption Curve, the US, 1976-2006 8
Figure 7: Head and Neck Cancer, Global, Market Forecasts ($bn), 20092020 10
Figure 8: Oncology Incidence (in billion), Global, 2008-2030 11
Figure 9: Head and Neck Cancer Incidence (in billion), Global, 2008-2030 11
Figure 10: Broad Classification of Head and Neck Cancer 13
Figure 11: Detailed TNM Classification of Oral Cavity Cancer 14
Figure 12: Detailed TNM Classification of Laryngeal Cancer 15
Figure 13: Detailed TNM Classification of Oropharyngeal Cancer 16
Figure 14: Detailed TNM Classification of Hypopharyngeal Cancer 17
Figure 15: Detailed TNM Classification of Nasopharyngeal Cancer 19
Figure 16: Classification of Head and Neck Cancer 20
Figure 17: Drug Model Diagram of Nimotuzumab 27
Figure 18: Nimotuzumab , Head and Neck cancer, Global Sales Forecast ($m), 20152020 28
Figure 19: Nimotuzumab , Head and Neck cancer, the US Sales Forecast ($m), 20152020 29
Figure 20: Nimotuzumab , Head and Neck cancer, the UK Sales Forecast ($m), 20152020 30
Figure 21: Nimotuzumab , Head and Neck cancer, France Sales Forecast ($m), 20152020 31
Figure 22: Nimotuzumab , Head and Neck cancer, Germany Sales Forecast ($m), 20152020 32
Figure 23: Nimotuzumab , Head and Neck cancer, Italy Sales Forecast ($m), 20152020 33
Figure 24: Nimotuzumab , Head and Neck cancer, Spain Sales Forecast ($m), 20152020 34
Figure 25: Nimotuzumab , Head and Neck cancer, Japan Sales Forecast ($m), 20152020 35
Figure 26: Global Sales Distribution of Nimotuzumab ($ mn), 2020 36
Figure 27: GlobalData Methodology 38
Figure 28: Drug Model Diagram 40
Figure 29: Patients Approved for the Drug 40

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *